Lijuan Feng MD, Siqi Li MD, Chaoran Wang MD, Jigang Yang MD, PhD
{"title":"神经母细胞瘤分子影像学及治疗的现状与展望","authors":"Lijuan Feng MD, Siqi Li MD, Chaoran Wang MD, Jigang Yang MD, PhD","doi":"10.1053/j.semnuclmed.2022.12.004","DOIUrl":null,"url":null,"abstract":"<div><p><span><span><span>Neuroblastoma is the most common extracranial </span>solid tumor<span> in children and arises from anywhere along the sympathetic nervous system. It is a highly heterogeneous disease with a wide range of prognosis, from </span></span>spontaneous regression<span> or maturing to highly aggressive. About half of pediatric<span><span> neuroblastoma patients develop the metastatic disease at diagnosis, which carries a poor prognosis. Nuclear medicine plays a pivotal role in the diagnosis, staging, response assessment, and long-term follow-up of neuroblastoma. And it has also played a prominent role in the </span>treatment<span><span> of neuroblastoma. Because the structure of metaiodobenzylguanidine (MIBG) is similar to that of </span>norepinephrine, 90% of neuroblastomas are MIBG-avid. </span></span></span></span><sup>123</sup><span><span><span>I-MIBG whole-body scintigraphy is the standard nuclear imaging technique for neuroblastoma, usually in combination with SPECT/CT. However, approximately 10% of neuroblastomas are MIBG nonavid. </span>PET<span> imaging has many technical advantages over SPECT<span> imaging, such as higher spatial and temporal resolution, higher sensitivity, superior quantitative capability, and whole-body tomographic imaging. In recent years, various tracers have been used for imaging neuroblastoma with PET. The importance of patient-specific </span></span></span>targeted radionuclide therapy for neuroblastoma therapy has also increased. </span><sup>131</sup><span><span>I-MIBG therapy is part of the front-line treatment for children with high-risk neuroblastoma. And peptide receptor </span>radionuclide therapy<span><span> with radionuclide-labeled somatostatin analogues<span> has been successfully used in the therapy of neuroblastoma. Moreover, radioimmunoimaging has important applications in the diagnosis of neuroblastoma, and radioimmunotherapy may provide a novel treatment modality against neuroblastoma. This review discusses the use of current and novel </span></span>radiopharmaceuticals in nuclear medicine imaging and therapy of neuroblastoma.</span></span></p></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":"{\"title\":\"Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma\",\"authors\":\"Lijuan Feng MD, Siqi Li MD, Chaoran Wang MD, Jigang Yang MD, PhD\",\"doi\":\"10.1053/j.semnuclmed.2022.12.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span><span>Neuroblastoma is the most common extracranial </span>solid tumor<span> in children and arises from anywhere along the sympathetic nervous system. It is a highly heterogeneous disease with a wide range of prognosis, from </span></span>spontaneous regression<span> or maturing to highly aggressive. About half of pediatric<span><span> neuroblastoma patients develop the metastatic disease at diagnosis, which carries a poor prognosis. Nuclear medicine plays a pivotal role in the diagnosis, staging, response assessment, and long-term follow-up of neuroblastoma. And it has also played a prominent role in the </span>treatment<span><span> of neuroblastoma. Because the structure of metaiodobenzylguanidine (MIBG) is similar to that of </span>norepinephrine, 90% of neuroblastomas are MIBG-avid. </span></span></span></span><sup>123</sup><span><span><span>I-MIBG whole-body scintigraphy is the standard nuclear imaging technique for neuroblastoma, usually in combination with SPECT/CT. However, approximately 10% of neuroblastomas are MIBG nonavid. </span>PET<span> imaging has many technical advantages over SPECT<span> imaging, such as higher spatial and temporal resolution, higher sensitivity, superior quantitative capability, and whole-body tomographic imaging. In recent years, various tracers have been used for imaging neuroblastoma with PET. The importance of patient-specific </span></span></span>targeted radionuclide therapy for neuroblastoma therapy has also increased. </span><sup>131</sup><span><span>I-MIBG therapy is part of the front-line treatment for children with high-risk neuroblastoma. And peptide receptor </span>radionuclide therapy<span><span> with radionuclide-labeled somatostatin analogues<span> has been successfully used in the therapy of neuroblastoma. Moreover, radioimmunoimaging has important applications in the diagnosis of neuroblastoma, and radioimmunotherapy may provide a novel treatment modality against neuroblastoma. This review discusses the use of current and novel </span></span>radiopharmaceuticals in nuclear medicine imaging and therapy of neuroblastoma.</span></span></p></div>\",\"PeriodicalId\":21643,\"journal\":{\"name\":\"Seminars in nuclear medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2023-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in nuclear medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0001299822001167\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0001299822001167","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma
Neuroblastoma is the most common extracranial solid tumor in children and arises from anywhere along the sympathetic nervous system. It is a highly heterogeneous disease with a wide range of prognosis, from spontaneous regression or maturing to highly aggressive. About half of pediatric neuroblastoma patients develop the metastatic disease at diagnosis, which carries a poor prognosis. Nuclear medicine plays a pivotal role in the diagnosis, staging, response assessment, and long-term follow-up of neuroblastoma. And it has also played a prominent role in the treatment of neuroblastoma. Because the structure of metaiodobenzylguanidine (MIBG) is similar to that of norepinephrine, 90% of neuroblastomas are MIBG-avid. 123I-MIBG whole-body scintigraphy is the standard nuclear imaging technique for neuroblastoma, usually in combination with SPECT/CT. However, approximately 10% of neuroblastomas are MIBG nonavid. PET imaging has many technical advantages over SPECT imaging, such as higher spatial and temporal resolution, higher sensitivity, superior quantitative capability, and whole-body tomographic imaging. In recent years, various tracers have been used for imaging neuroblastoma with PET. The importance of patient-specific targeted radionuclide therapy for neuroblastoma therapy has also increased. 131I-MIBG therapy is part of the front-line treatment for children with high-risk neuroblastoma. And peptide receptor radionuclide therapy with radionuclide-labeled somatostatin analogues has been successfully used in the therapy of neuroblastoma. Moreover, radioimmunoimaging has important applications in the diagnosis of neuroblastoma, and radioimmunotherapy may provide a novel treatment modality against neuroblastoma. This review discusses the use of current and novel radiopharmaceuticals in nuclear medicine imaging and therapy of neuroblastoma.
期刊介绍:
Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.